FOLD · As filed with the SEC
Amicus Therapeutics income statement, by fiscal year
The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Net product sales | 634,210 | 528,295 | 399,356 | 329,233 | 305,514 | — | — | — |
| Cost of goods sold | 72,929 | 52,943 | 37,326 | 38,599 | 34,466 | 31,044 | 21,963 | 14,404 |
| Gross profit | 561,281 | 475,352 | 362,030 | 290,634 | 271,048 | 229,842 | 160,274 | 76,841 |
| Operating expenses: | ||||||||
| Research and development | 135,843 | 109,362 | 152,381 | 276,677 | 272,049 | 308,443 | 286,378 | 270,902 |
| Selling, general, and administrative | 383,487 | 323,379 | 275,270 | 213,041 | 192,710 | 156,407 | 169,861 | 127,200 |
| Changes in fair value of contingent consideration payable | 0 | 0 | 2,583 | 1,078 | 6,514 | 3,144 | 3,297 | 3,300 |
| Depreciation and amortization | — | — | — | — | 6,209 | 8,846 | 4,775 | — |
| Loss on impairment of assets | 1,702 | 0 | 1,134 | 6,616 | — | — | 0 | 0 |
| Restructuring charges | 0 | 9,188 | — | — | — | — | — | 0 |
| Depreciation | — | — | — | — | — | — | — | 4,216 |
| Depreciation and amortization | 7,460 | 8,547 | 7,873 | 5,342 | — | — | — | — |
| Total operating expenses | 528,492 | 450,476 | 439,241 | 502,754 | 477,482 | 476,840 | 464,311 | 405,618 |
| Income (loss) from operations | 32,789 | 24,876 | (77,211) | (212,120) | (206,434) | (246,998) | (304,037) | (328,777) |
| Other (expense) income: | ||||||||
| Interest income | 3,317 | 5,407 | 7,078 | 3,024 | 509 | 3,226 | 10,249 | 10,461 |
| Interest expense | — | — | (50,149) | (37,119) | (32,471) | (22,425) | (18,872) | (22,402) |
| Change in fair value of derivatives | — | — | — | — | — | — | — | (2,739) |
| Loss on extinguishment of debt | — | — | — | — | — | — | — | 0 |
| Loss on exchange of convertible notes | — | — | — | — | 0 | 0 | — | — |
| Interest expense | (46,159) | (49,598) | — | — | — | — | — | — |
| Loss on extinguishment of debt | 0 | 0 | (13,933) | 0 | (257) | (7,276) | (40,624) | — |
| Change in fair value of derivatives | — | — | — | — | — | 0 | 0 | — |
| Other (expense) income | 10,244 | (9,441) | (15,886) | 4,176 | (2,901) | (781) | (2,626) | (5,632) |
| Income (loss) before income tax | 191 | (28,756) | (150,101) | (242,039) | (241,554) | (274,254) | (355,910) | (349,089) |
| Income tax expense | (27,301) | (27,350) | (1,483) | 5,471 | (8,906) | (2,598) | (478) | 94 |
| Net loss attributable to common stockholders | (27,110) | (56,106) | (151,584) | (236,568) | (250,460) | (276,852) | (356,388) | (348,995) |
| Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share) | — | — | — | — | — | (1.07) | (1.48) | (1.88) |
| Weighted-average common shares outstanding - basic and diluted (in shares) | — | — | — | — | — | 258,867,380 | 240,421,001 | 185,790,021 |
| Net loss attributable to common stockholders per common share - basic (in dollars per share) | (0.09) | (0.18) | (0.51) | (0.82) | (0.92) | — | — | — |
| Net loss attributable to common stockholders per common share - diluted (in dollars per share) | (0.09) | (0.18) | (0.51) | (0.82) | (0.92) | — | — | — |
| Weighted-average common shares outstanding - basic (in shares) | 308,363,768 | 304,380,502 | 295,164,515 | 289,057,198 | 271,421,986 | — | — | — |
| Weighted-average common shares outstanding - diluted (in shares) | 308,363,768 | 304,380,502 | 295,164,515 | 289,057,198 | 271,421,986 | — | — | — |
| Net product sales | — | — | — | — | — | 260,886 | 182,237 | 91,245 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.